Salivary Aldosterone as a Diagnostic Aid in Primary Aldosteronism

Abstract

Recent evidence demonstrates an increased incidence of primary aldosteronism (PA) in approximately 10% of the hypertensive population, making noninvasive and simple screening methods necessary. The aim of the present study was to apply a time-resolved fluorescence immunoassay for the measurement of aldosterone in saliva and the establishment of a cut-off to identify patients with a high likelihood for PA requiring subsequent screening with the aldosterone to renin ratio. Saliva was collected (AM and PM) to ascertain an optimum time with best discriminating power between healthy and disease states. Plasma aldosterone, after overnight recumbency and 4 h later, was collected for posture testing. The participants included 53 PA patients (aged 14–78), 54 with essential hypertension (EH, aged 19–82), and 38 healthy volunteers (aged 19–56). Saliva aldosterone (SA) (median, 25–75^th%) in PA was found at 90 pg/ml (61–139) compared to 53 pg/ml (40–85) in EH, with discrimination between PA versus EHs best in the morning (cutoff: 81 pg/ml, 77% sensitivity, 82% specificity). Saliva aldosterone decreases throughout the day in patients with adenomas [APA AM: 123 pg/ml (92–213) vs. PM: 79 pg/ml (41–116)], but not in those with bilateral hyperplasia [BAH AM: 85 pg/ml (59–115)] vs. pm 69 pg/ml (57–114). Morning SA alone allows discrimination between PA and controls, though with significant overlap against EHs, leading to a high number of false positives. More promising is the use of diurnal variation in SA in distinguishing between APA and BAH. The decline in SA seen in patients with APA presents a more constant finding compared to posture testing, which fails to correctly classify a large number of patients.

Key words

aldosterone - steroid hormones - renin-angiotensin-aldosterone system - hypertension

References

• 1 Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.  Mol Cell Endocrinol. 2004;  217 53-58
• 2 Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons.  N Engl J Med. 2004;  351 33-41
• 3 Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis.  Horm Metab Res. 2008;  40 435-441
• 4 Skott O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL. Rapid actions of aldosterone in vascular health and disease – friend or foe?.  Pharmacol Ther. 2006;  111 495-507
• 5 Marcy TR, Ripley TL. Aldosterone antagonists in the treatment of heart failure.  Am J Health Syst Pharm. 2006;  63 49-58
• 6 Krug AW, Ehrhart-Bornstein M. Adrenocortical dysfunction in obesity and the metabolic syndrome.  Horm Metab Res. 2008;  40 515-517
• 7 Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients.  J Hypertens. 2003;  21 2149-2157
• 8 Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor.  Trends Endocrinol Metab. 2005;  16 104-107
• 9 Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young Jr WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.  J Clin Endocrinol Metab. 2004;  89 1045-1050
• 10 Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity.  Clin Chem. 2005;  51 386-394
• 11 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.  J Clin Endocrinol Metab. 2008;  93 3266-3281
• 12 Few JD, Wallis PJ, James VH. The relationship between salivary aldosterone and plasma free aldosterone concentrations.  Clin Endocrinol (Oxf). 1986;  24 119-126
• 13 McVie R, Levine LS, New MI. The biological significance of aldosterone concentration in saliva.  Pediat Res. 1979;  13 755-759
• 14 Few JD, Chaudry S, James VH. The direct determination of aldosterone in human saliva.  J Steroid Biochem. 1984;  21 87-92
• 15 Few JD, Unwin RJ, Carmichael DJ, James VH. Diurnal fluctuation in saliva aldosterone concentration.  J Steroid Biochem. 1987;  26 265-271
• 16 Hubl W, Taubert H, Freymann E, Hofmann F, Meissner D, Garten CD, Schmidt PK, Thiele HJ, Neef B. A simple solid phase enzyme immunoassay for aldosterone in plasma and saliva.  Exp Clin Endocrinol. 1983;  82 188-193
• 17 Atherden SM, Corrie JE, Jones DB, Al-Dujaili EA, Edwards CR. Development and application of a direct radioimmunoassay for aldosterone in saliva.  Steroids. 1985;  46 845-855
• 18 Dressendorfer RA, Strasburger CJ, Bidlingmaier F, Klug I, Kistner A, Siebler T, Kiess W. Development of a highly sensitive nonisotopic immunoassay for the determination of salivary 17-hydroxyprogesterone: reference ranges throughout childhood and adolescence.  Pediatr Res. 1998;  44 650-655
• 19 Kooner JS, Few JD, Lee CY, Taylor GM, James VH. Investigation of the salivary 18-hydroxycorticosterone: aldosterone ratio in man using a direct assay.  J Steroid Biochem Mol Biol. 1991;  38 377-382
• 20 Born-Frontsberg E, Reincke M, Beuschlein F, Quinkler M. Tumor size of Conn's adenoma and comorbidities.  Horm Metab Res. 2009;  41 785-788
• 21 Schambelan M, Brust NL, Chang BC, Slater KL, Biglieri EG. Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism.  J Clin Endocrinol Metab. 1976;  43 115-131
• 22 Espiner EA, Ross DG, Yandle TG, Richards AM, Hunt PJ. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling.  J Clin Endocrinol Metab. 2003;  88 3637-3644
• 23 Mulatero P, Bertello C, Rossato D, Mengozzi G, Milan A, Garrone C, Giraudo G, Passarino G, Garabello D, Verhovez A, Rabbia F, Veglio F. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes.  J Clin Endocrinol Metab. 2008;  93 1366-1371
• 24 Manolopoulou J, Mulatero P, Maser-Gluth C, Rossignol P, Spyroglou A, Vakrilova Y, Petersenn S, Zwermann O, Plouin PF, Reincke M, Bidlingmaier M. Saliva as a medium for aldosterone measurement in repeated sampling studies.  Steroids. 2009;  74 853-858
• 25 Stowasser M, Klemm SA, Tunny TJ, Gordon RD. Plasma aldosterone response to ACTH in subtypes of primary aldosteronism.  Clin Exp Pharmacol Physiol. 1995;  22 460-462
• 26 Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F. Renal damage in primary aldosteronism: results of the PAPY Study.  Hypertension. 2006;  48 232-238
• 27 Ganguly A, Dowdy AJ, Luetscher JA, Melada GA. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma.  J Clin Endocrinol Metab. 1973;  36 401-404
• 28 Plamondon I, Agharazii M, Douville P, Lebel M. Morning plasma aldosterone predicts the subtype of primary aldosteronism independent of sodium intake.  Clin Exp Hypertens. 2007;  29 127-134
• 29 Young Jr WF, Klee GG. Primary aldosteronism. Diagnostic evaluation.  Endocrinol Metab Clin North Am. 1988;  17 367-395

Correspondence